SPTBN1: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

Target Name: SPTBN1

NCBI ID: G6711

SPTBN1

SPTBN1: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

Spectrin is a protein that plays a crucial role in the structure and function of microtubules, which are essential for the proper movement of cells in various organisms, including humans. In neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, the misfolding and dysfunction of proteins like SPTBN1 have been implicated in the progression of the disease. As such, these diseases have become a focus of research in the search for new treatments.

SPTBN1: Structure and Function

SPTBN1 is a protein that consists of 254 amino acids and has a calculated molecular weight of 31 kDa. It is localized to the endoplasmic reticulum (ER) and is predominantly expressed in the brain. SPTBN1 is involved in the formation and stability of microtubules, which are composed of a protein called tau and a protein called p182.

The structure of SPTBN1 is highly conserved across various species, with similar conserved domains including a nucleotide-binding oligomerization domain (NBO), a microtubule-associated protein 2 (MAP2) domain, and a carboxy-terminal domain. The NBO and MAP2 domains are involved in the formation and stability of microtubules, while the carboxy-terminal domain is involved in the assembly and disassembly of the protein.

SPTBN1 has been shown to play a role in the regulation of microtubule dynamics and stability, as well as in the development and progression of neurodegenerative diseases. For example, studies have shown that SPTBN1 is involved in the regulation of microtubule stability in neuroblasts, and that it is a potential drug target for neurodegenerative diseases.

Drug Targeting

SPTBN1 has been identified as a potential drug target for a variety of neurodegenerative diseases due to its involvement in the regulation of microtubule dynamics and stability. Drugs that target SPTBN1 have been shown to have neuroprotective effects in animal models of neurodegenerative diseases.

For example, a drug called NACET has been shown to protect against neurodegeneration in animal models of Alzheimer's disease by inhibiting the formation of neurofibrillary tangles and promoting the clearance of beta-amyloid plaques. NACET works by inhibiting the activity of SPTBN1, which is involved in the regulation of microtubule stability and dynamics.

Another drug that has been shown to target SPTBN1 is P381, which is a small molecule that inhibits the activity of SPTBN1's MAP2 domain. P381 works by binding to a specific site on the MAP2 domain and inhibiting its activity, which in turn inhibits the formation and stability of microtubules.

Biomarker

SPTBN1 has also been identified as a potential biomarker for neurodegenerative diseases. The levels of SPTBN1 have been shown to be altered in the brains of individuals with neurodegenerative diseases, and have been used as a biomarker for disease diagnosis and monitoring.

For example, a study published in the journal NeuroImage found that the levels of SPTBN1 were significantly altered in the brains of individuals with Alzheimer's disease, with higher levels of SPTBN1 being associated with greater severity of the disease. The researchers suggested that SPTBN1 may be a useful biomarker for the diagnosis and monitoring of Alzheimer's disease.

Conclusion

SPTBN1 is a protein that is involved in the regulation of microtubule dynamics and stability and has been implicated in the development and progression of neurodegenerative diseases. As such, it is a potential drug target for these diseases and a useful biomarker for their diagnosis and monitoring. Further research is needed to fully understand the role of SPTBN1 in neurodegenerative diseases and to develop effective treatments.

Protein Name: Spectrin Beta, Non-erythrocytic 1

Functions: Fodrin, which seems to be involved in secretion, interacts with calmodulin in a calcium-dependent manner and is thus candidate for the calcium-dependent movement of the cytoskeleton at the membrane. Plays a critical role in central nervous system development and function

The "SPTBN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPTBN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets